EquiPure LH™
Product Overview
EquiPure LH™ is a novel single-chain LH analog for horses. It is designed to induce ovulation in estrous mares thereby providing better overall breeding management and convenience to breeders. It is anticipated to be our first FDA approved product based upon our late 2005 INADA filing with the FDA. We began gaining revenue from this product in late 2005 by selling it as a specially labeled reagent to licensed veterinarians and expect to continue to sell it until it gains final FDA approval, which is expected by late 2008. This first FDA approval is important for us, as it will pave the way by creating the framework, for the approvals of all future single-chain drugs we submit to FDA. As a recombinant hormone drug, this product will be prescribed and administered by licensed veterinarians; the ultimate customers will be horse owner clients and clients operating breeding farms. Current estimates indicate that the total US equine ovulation market may exceed 700,000 doses consisting of 350,000 mares receiving approximately two doses annually. The total annual US market potential is estimated at approximately $17 to $20 million. We would expect to market this drug through a larger partner who would share in such revenues.
